Khayat-Khoei M, et al.J Neurol. 2021 Sep 4:1-14. doi: 10.1007/s00415-021-10780-7. Online ahead of print.J Neurol. 2021.PMID: 34480607
. Wightman DP, et al.Nat Genet. 2021 Sep;53(9):1276-1282. doi: 10.1038/s41588-021-00921-z. Epub 2021 Sep 7.Nat Genet. 2021.PMID: 34493870
.
Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. American Journal of Therapeutics, 28, e434-e460, July 2021.
Bryant A, Lawrie TA, Fordham EJ.
.
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW; COV-BARRIER Study Group.
. Jena A, et al.Autoimmun Rev. 2021 Aug 30:102927. doi: 10.1016/j.autrev.2021.102927. Online ahead of print.Autoimmun Rev. 2021.PMID: 34474172
.
.
.
Current status of drug resistance & phage types of Salmonella typhi in India.